Teva 和 mAbxience加强全球伙伴关系,发展反PD-1肿瘤生物相似的病原体。 Teva and mAbxience strengthen global partnership to develop anti-PD-1 oncology biosimilar.

通过新的全球许可协议, Teva 制药和 mAbxience 加强了合作伙伴关系, 开发一种抗PD-1 瘤生物类似药. Teva Pharmaceuticals and mAbxience have strengthened their partnership with a new global licensing agreement to develop an anti-PD-1 oncology biosimilar. 该倡议标志着它们的第二次合作,侧重于生产负担得起的、高质量的肿瘤治疗。 This initiative, marking their second collaboration, focuses on producing affordable, high-quality treatments for oncology. 据了解,mAbxience将在西班牙和阿根廷负责开发和生产,而Teva将在美国和欧洲管理监管批准和商业化,与Teva的增长战略保持一致. mAbxience will handle development and production in Spain and Argentina, while Teva will manage regulatory approvals and commercialization in the U.S. and Europe, aligning with Teva's growth strategy.

October 03, 2024

7 文章